FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy

The FDA will hold an advisory committee meeting for Sarepta’s investigational gene therapy for Duchenne muscular dystrophy ahead of its May 29, 2023 action date.